The AIDS Clinical Trials Group, funded by the National Institute of Allergy and Infectious Diseases (NIAID), has started the first clinical trial testing a combined method of anti-HIV antibodies plus a long-acting antiretroviral medication as long-acting HIV treatment. Researchers are exploring the use of HIV antibodies for their potential to stop a wide variety of HIV strains from infecting immune cells. The implications of a long-acting HIV treatment could make viral suppression more realistic for those who have difficulty taking a daily drug regimen.
Read more about the clinical trial on HIV.gov.